Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Synthesis
Enzyme Targets Continued
July 19, 2010
| A version of this story appeared in
Volume 88, Issue 29
I read with interest Mike Renier’s letter to the editor on pyruvate kinase (C&EN, May 17, page 5).
I’m a biochemist, and I have wondered why NAD kinase (only enzyme to produce NADP) has not been targeted for cancer therapy. This approach might be more effective than other kinase inhibitors such as pyruvate kinase.
The pharmaceutical companies have a library of kinase inhibitors. They might want to include NAD kinase inhibitors in their lists.
Jim Butler
Tucson
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter